20 June 2024
Incanthera plc
("Incanthera" the "Company")
Result of General Meeting
Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the results of a general meeting ("General Meeting") held at 11am today.
The General Meeting follows the company's announcement on 3 June 2024, of a conditional subscription for
The Company is pleased to announce that all resolutions were duly passed.
For further information please contact:
|
Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communications |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
|
|
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes |
+44 (0) 20 7213 0880 |
|
|
|
|
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
